| Methods | n = 102, 31 centres Allocation concealment: not described Baseline similarity: age (D), SAPS II, sepsis Blinding: caregivers Cointerventions: Nitric oxide applied according to protocol Withdrawals: none Losses to follow‐up: none |
|
| Participants | Inclusions: AECC definition for ARDS; duration of ARDS < 24 hours Exclusions: Recent MI; chronic congestive heart failure; liver or renal failure; pneumonectomy; neurogenic pulmonary edema; neutropenia |
|
| Interventions | IV liposomal PGE1, dose titrated to 1.8 mcg/kg every 6 hours (7.2 mcg/kg/day) for 7 days, or placebo | |
| Outcomes | 28 day mortality: RR 1.07 (95% CI 0.55 to 2.06) Duration of ventilation (days; not stated whether median or mean): 16 (PGE1 group); 16.6 (placebo group); p = 0.94 Adverse events leading to discontinuation of therapy (details not given): treatment: 8/70, control: 2/32 |
|
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.